Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has bolstered its pursuit of novel cancer treatments by appointing five renowned oncology and drug development experts to its Clinical Advisory Board, with a concerted effort on advancing pancreatic cancer trials. The esteemed board, led by Dr. Jose Iglesias, will shape the company’s international clinical trial strategies, leveraging the potential of Amplia’s leading drug candidate, narmafotinib. This move marks a significant advancement for Amplia, highlighting their commitment to addressing the urgent need for new therapies in pancreatic cancer treatment.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
